NuVasive (NASDAQ:NUVA) will issue its quarterly earnings data after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of $0.42 per share for the quarter. NuVasive has set its FY 2019 guidance at $2.20-2.30 EPS and its FY19 guidance at $2.20-2.30 EPS.Parties interested in participating in the company’s conference call can do so using this link.
NuVasive (NASDAQ:NUVA) last posted its quarterly earnings data on Wednesday, February 20th. The medical device company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.06. The firm had revenue of $288.30 million for the quarter, compared to analysts’ expectations of $290.85 million. NuVasive had a return on equity of 14.60% and a net margin of 1.13%. The company’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.56 EPS. On average, analysts expect NuVasive to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
NUVA stock opened at $59.85 on Monday. The company has a current ratio of 3.44, a quick ratio of 1.92 and a debt-to-equity ratio of 0.72. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of 26.84, a PEG ratio of 2.24 and a beta of 1.21. NuVasive has a fifty-two week low of $43.51 and a fifty-two week high of $72.41.
NUVA has been the topic of several recent research reports. BTIG Research lowered their price objective on NuVasive to $59.00 and set a “buy” rating on the stock in a research report on Thursday, January 17th. They noted that the move was a valuation call. Needham & Company LLC cut NuVasive from a “buy” rating to a “hold” rating in a research report on Friday, February 8th. Morgan Stanley decreased their price target on NuVasive from $73.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 2nd. Jefferies Financial Group cut NuVasive from a “buy” rating to a “hold” rating and set a $60.00 price target on the stock. in a research report on Tuesday, February 12th. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $50.00 price target on shares of NuVasive in a research report on Monday, February 11th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $66.64.
WARNING: “NuVasive (NUVA) Scheduled to Post Quarterly Earnings on Wednesday” was first reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://transcriptdaily.com/2019/04/29/nuvasive-nuva-scheduled-to-post-quarterly-earnings-on-wednesday.html.
NuVasive Company Profile
NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Recommended Story: What causes a recession?
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.